Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders ...Middle East

CHEYNEY, Pa., Aug. 9, 2021 /PRNewswire/ -- Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities....

Hence then, the article about navrogen closes 3 0m seed financing to advance its preclinical pipeline targeting humoral immunosuppressed cancers and immune related disorders was published today ( Monday 09/08/2021 - 05:03 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders )

Also on site :

• Inside the chaos at Canoo, the zero-revenue, cash-burning EV company that just inked a major deal with Walmart
• Zelensky’s inner circle accused of war profiteering
• Rolling Stones Mick Jagger, Keith Richards, and Ronnie Wood Have the Time of Their Life on the Red Carpet